Oral or transdermal opioids vs placebo: Adverse events as N of participants with at least one adverse event objective
Oral or transdermal opioids probably leads to higher number of participants experiencing any adverse event (median compared with placebo (moderate certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Oral or transdermal opioids vs placebo Number of participants experiencing any adverse event (median · participants with osteoarthritis of the knee or hip Oral or transdermal opioids probably leads to higher number of participants experiencing any adverse event (median compared with placebo (moderate certainty). Oral or transdermal opioids for osteoarthritis of the knee or hip (2014) · Cochrane Headline outcomes only | RR 1.49 [1.35, 1.63] | 9 studies · 4898 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Oral or transdermal opioids for osteoarthritis of the knee or hip 2014 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.